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Abstract
Background: RNA-binding proteins accompany all steps in the life of mRNAs and provide dynamic gene regulatory
functions for rapid adjustment to changing extra- or intracellular conditions. The association of RNA-binding proteins with
their targets is regulated through changing subcellular distribution, post-translational modification or association with other
proteins.
Methodology: We demonstrate that the dsRNA binding protein 76 (DRBP76), synonymous with nuclear factor 90, displays
inherently distinct tissue type-specific subcellular distribution in the normal human central nervous system and in malignant
brain tumors of glial origin. Altered subcellular localization and isoform distribution in malignant glioma indicate that
tumor-specific changes in DRBP76-related gene products and their regulatory functions may contribute to the formation
and/or maintenance of these tumors. To identify endogenous mRNA targets of DRBP76, we performed RNA-
immunoprecipitation and genome-wide microarray analyses in HEK293 cells, and identified specific classes of transcripts
encoding critical functions in cellular metabolism.
Significance: Our data suggest that physiologic DRBP76 expression, isoform distribution and subcellular localization are
profoundly altered upon malignant transformation. Thus, the functional role of DRBP76 in co- or post-transcriptional gene
regulation may contribute to the neoplastic phenotype.
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Introduction
All mRNA functions, starting with biogenesis, co-transcriptional
processing, nuclear export, subcellular distribution, translation and
ending with decay, involve association with RNA-binding proteins
forming discrete ribonucleo-protein (RNP) complexes [1,2].
Therefore, through binding to functionally related transcripts,
individual RNA-binding proteins have the potential for affecting
gene regulation by coordinating control over mRNA function [3].
The interleukin enhancer binding factor 3 (ILF3) gene encodes a
variety of related proteins in cultured cells with apparent sizes of
110 kDa (termed ILF3 [4] or nuclear factor associated with
dsRNA-2 (NFAR-2) [5]) and 90 kDa (termed nuclear factor (NF)
90 [6,7], DRBP76 [8] or NFAR-1 [5]). Diverse NFAR proteins
originate from alternative splicing in the 39 portion of ILF3
transcripts (Fig. 1A). For clarity, we will refer to the 110 kDa and
90 kDa proteins as ILF3 and DRBP76, respectively. Both proteins
are known to associate with nuclear factor 45 (NF45), forming the
nuclear factor of activated T-cells (NFAT; [9]). NFAR proteins
contain nucleic acid binding motifs [8] and were originally
identified because of their association with the interleukin-2
promoter [7]. They have been implicated in transcriptional
regulation, although their precise role in this process remains
poorly defined [10]. In addition, DRBP76 contains two double-
stranded (ds) RNA binding motifs [11]. Complementing its
involvement in transcriptional regulation, many lines of evidence
point to a role for DRBP76 in post-transcriptional gene regulation
due to its RNA-binding capacity.
DRBP76 has been suggested to interact with a variety of cellular
or viral RNAs, both in the nucleus and in the cytoplasm (reviewed
in [12]). It was identified in screens for AU-rich element (ARE)-
binding proteins [13,14], but its various proposed target mRNAs
generally do not share apparent recognition signals. Association
with DRBP76 in the cytoplasm has been shown to stabilize target
mRNAs [14,15] and to influence their translation [14,16–20].
However, based on disparate observations in diverse empirical
systems, no uniform role in post-transcriptional gene control has
been assigned to NFAR proteins.
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nucleus [21] and, thus, obvious that any function in post-
transcriptional gene regulation relates to its subcellular distribu-
tion. Based on studies in immortalized cultured cells of diverse
origin it has been suggested that DRBP76 is predominantly
nuclear and may translocate to the cytoplasm when prompted by
certain stimuli, e.g. post-translational modification during mitosis
[21]. It has been suggested that the subcellular distribution of
DRBP76 is in part determined by protein:RNA interactions in
either the nuclear or cytoplasmic compartments [21]. However,
there is emerging evidence that subcellular DRBP76 distribution
may vary inherently in a cell type-specific manner. This is evident
from studies with HEK293 cells, showing a predominantly
cytoplasmic distribution of the protein [11,12,18,19]. This raises
the possibility that DRBP76 assumes cell type- or organ-specific
roles in gene regulation.
We report here that DRBP76 exhibits strikingly distinct isoform
expression and subcellular distribution in the normal human
central nervous system (CNS) and in glial CNS malignancy,
reminiscent of earlier observations in cultured cells [18]. Abundant
cytoplasmic DRBP76 in normal CNS contrasts with exclusive
nuclear distribution in patients’ tumors. These observations
suggest that DRBP76’s involvement in gene regulation may vary
in a tissue type-specific manner. To define the pool of mRNAs
associating with DRBP76, we carried out RNA co-immunopre-
cipitation (IP)/micro-array (RIP-Chip) assays [22,23] in HEK293
cells. Our analyses revealed statistically significant associations of
DRBP76 with distinct classes of transcripts key to the regulation of
metabolism, DNA synthesis and cell proliferation.
Results
1. Tissue type-specific distribution of DRBP76 isoforms
We tested DRBP76 isoform distribution in an array of adult
mouse tissues (the anti-DRBP76 antibody used recognizes
primate/murine proteins alike; Fig. 1B, D). For orientation, a
proposed intron-exon organization of the ILF3 gene and the origin
of diverse NFAR proteins are shown (Fig. 1A). In general
agreement with previously published work [24], we detected
several proteins of a predicted size range of ,75–80 kDa
Figure 1. NFAR protein isoform- and subcellular distribution in normal and neoplastic tissues. A. Intron-exon organization of the ILF3
gene [25,33]. Exons are indicated by black boxes (top); alternative splicing yields diverse transcripts encoding DRBP76/ILF3 proteins with distinct C-
termini (bottom; coding sequences are indicated by solid boxes). Hatched lines indicate proposed alternative splicing of exon 3 [25]. B. DRBP76
immunoblot of HeLa or HEK293 cell lysates (lanes 1–2) or non-fractionated murine tissue extracts of the indicated origin (lanes 3–8). (Lanes 9–10)
DRBP76 immunoblot of normal Cynomologus brain (cyno) and NHA cell lysate. C. DRBP76 immunoblots of HEK293 and HTB-14 glioma cell lysates
(lanes 1, 2) and total extracts prepared from normal cortex (3, 6=frontal; 4, 7=temporal; 5=parietal) of human (h.s.) or simian (cyno) brain or human
GBM tissue samples (8–13). Asterisks indicate histopathologically confirmed contamination with normal CNS. D. NFAR protein immunoblot analyzed
with 7% tris-acetate gel electrophoresis. Simian (cyno) and fractionated cytoplasmic and nuclear murine (m.) brain extracts were studied in parallel
with HEK293 lysates. Protein bands are labeled in (E). E. Evaluation of NFAR proteins in fractionated, cytoplasmic extracts from human normal brain
and GBM tissues. Immunoblot filters were deliberately over-exposed to reveal all DRBP76-immunoreactive material. sc35 is a nuclear spliceosome
component. F. DRBP76 immunoblot from fractionated extracts of the indicated cell lines. SH-SY5Y (SY5Y) cells were untreated or treated to induce a
neuronal phenotype with ATRA.
doi:10.1371/journal.pone.0011710.g001
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all organs tested (Fig. 1B). However, our analyses suggest that
DRBP76 is substantially more abundant in the nervous system and
spleen compared to other organ systems. This is particularly
obvious when considering the ILF3:DRBP76 expression differen-
tial in individual organs (e.g., brain vs. liver). We carefully
normalized tissue lysates for total protein content and controlled
our assay by evaluating the levels of several marker proteins,
including tubulin (Fig. 1B) and eukaryotic initiation factor 4A (not
shown). Moreover, our analyses suggested that DRBP76 proteins,
but not ILF3, differ in apparent size in normal adult mouse tissues
and in human transformed cell lines (Fig. 1B).
To corroborate these findings, we further evaluated DRBP76
proteins in a major expression site, the CNS. We tested normal
human brain tissues from various brain regions obtained at
autopsy (Fig. 1C, lanes 3–5). Due to concerns with possible post-
mortem degradation of the sample, we included brain from
Cynomolgus macaques, tissues that were fresh frozen immediately
upon euthanasia and dissection of the brain (Fig. 1C, lanes 6, 7).
Paralleling earlier studies with representative cell lines of
spontaneous tumors of astrocytic lineage [18], we also evaluated
DRBP76 distribution in tissues from patients diagnosed with
primary CNS tumors, i.e. glioblastoma multiforme (GBM). Under
the specific electrophoresis conditions employed we distinguished
at least two major DRBP76 isoforms of ,75 to 80 kDa in normal
brain, while a single form of ,90 kDa predominates in HEK293
and HTB-14 glioma cells. A similar DRBP76 doublet in
immunoblots of mouse brain lysates has been observed previously
[25], but that study did not show comparison with cell lines.
Interestingly, all primary CNS tumors displayed NFAR protein
isoform distribution similar to transformed cell lines (Fig. 1C, lanes
8–13). In some tumors a band reminiscent of the major ,80 kDa
sized protein in normal CNS was detected (Fig. 1C, asterisks), but
these samples contained contaminating normal brain, a frequent
occurrence in such samples that was indicated in the neuropa-
thologist’s report. These analyses suggest that physiologic DRBP76
isoform distribution is altered upon malignant transformation, at
least in the CNS. The appearance of NFAR proteins in primary
CNS tumors is comparable to transformed cells regardless of their
tissue origin (e.g. HeLa cells; Fig. 1B, lane 1), suggesting that
altered DRBP76 isoform distribution may occur in other
neoplasms. Since GBM is of glial origin, normal primate brain
may not be an appropriate non-malignant control tissue.
Therefore, we evaluated DRBP76 isoform distribution in normal
human astrocytes (NHA; Fig. 1B, lane 10). These cells recapitu-
lated the DRBP76 isoform distribution detected in normal brain
(compare Fig. 1B; lane 9). Therefore, altered DRBP76 isoform
expression in GBM is a true variation from the non-malignant
state and does not represent a glia-specific phenomenon. Also,
since primary explant human cells retain the DRBP76 isoform
pattern of their organ of origin, DRBP76 isoform patterns in HeLa
or HEK293 cells may reflect their transformed state.
2. Tissue type-specific subcellular localization of DRBP76
DRBP76 contains a functional nuclear localization signal and its
location is predominantly nuclear in many cultured cell lines [10].
It has been suggested that certain physiologic conditions, e.g. T-
cell activation [15] or mitosis [21], may trigger cytoplasmic
localization of the protein, possibly via post-translational modifi-
cation or modulation of RNA binding [21]. We showed previously
that ,90 kDa DRBP76 is enriched in the cytoplasm of cultured
cells of neuronal origin in the absence of known re-localization
triggers when compared to non-neuronal cells, e.g. malignant
glioma [18].
Extensive heterogeneity of NFAR proteins in mammalian brain
has been observed before [25] and may be due to splice variation
[25] and post-translational modifications, e.g., arginine methyla-
tion [26], lysine acetylation [27] or phosphorylation [8]. To better
resolve anti-DRBP76 immunoreactive material in the 75–90 kDa
size range and to begin assessing subcellular localization of NFAR
proteins in the normal CNS, we tested fractionated (cytoplasmic
vs. nuclear) tissue lysates by immunoblotting after gel electropho-
resis in 7% Tris-acetate gels (Fig. 1D). The characteristic doublet
of bands at ,80 kDa occurs in mouse and Cynomolgus macaque
brain and is clearly distinguishable from a band with larger
molecular size in HEK293 cells (Fig. 1D, lane 1). Exclusive
detection of the ,110 kDa band and less abundant ,80 kDa
material in nuclear extracts (Fig. 1D, lane 4) suggests that the
former may represent ILF3 and the latter to occur in the
cytoplasm.
To evaluate cytoplasmic DRBP76 in the normal human brain
and in GBM, we tested fractionated cytosolic extracts by
immunoblot (Fig. 1E). Surprisingly, while highly abundant in
normal brain (lanes 1–3), cytosolic DRBP76 of ,75–80 kDa was
absent from immunoblots of fractionated cytoplasmic human
GBM samples (lanes 4–6) (Fig. 1E). We included detection of sc35,
a nuclear spliceosome component, to evaluate the possibility of
nuclear contamination. These tests revealed readily detectable
nuclear contaminants in samples 1 (brain) and 4 (GBM), which
correlated with the presence of ILF3 in both samples (Fig. 1E,
lanes 1, 4). Judging from the band intensity in correlation with
sc35, ILF3 was roughly equally abundant in normal brain and in
GBM tissues. Our analyses indicate that the ,75–80 kDa
DRBP76 protein is abundant in normal human brain, and it is
absent, or below detection level, in tissues from primary CNS
tumors.
To test whether different subcellular distribution of DRBP76
occurs in transformed cells of diverse origin, we conducted
DRBP76 immunoblot studies in fractionated cell extracts from
HEK293 neuroblasts, SH-SY5Y neuroblastoma cells and HTB-14
glioma cells. Similar to previous reports, the bulk of DRBP76 was
present in nuclear fractions (Fig. 1F). However, there was
abundant cytoplasmic DRBP76 in the neuronally derived cell
lines, but hardly any cytoplasmic protein in HTB-14 cells (Fig. 1F).
Induction of a neuronal phenotype with all-trans retinoic acid
(ATRA) treatment of SH-SY5Y did not change the isoform
pattern or subcellular distribution of DRBP76 (Fig. 1F). These
findings suggest that transformed cell lines of neuronal origin
acquire the ‘malignant’ isoform pattern associated with primary
CNS tumors, but retain at least some cytoplasmic DRBP76
characteristic of normal CNS tissues.
To corroborate the different subcellular localization of DRBP76
proteins in normal human brain and in GBM, we conducted
immunofluorescence studies in both tissues. We assayed histo-
pathologically confirmed normal brain (Fig. 2A–T) and GBM free
of contaminating normal CNS tissue (Fig. 2U–W). Nissl substance,
abundant in neuronal cells, was readily detected by NeuroTrace
fluorescent stain in sections of normal human brain (Fig. 2A, F, K,
P). Immunostaining of the same sections with anti-DRBP76
(Fig. 2B, G, L) revealed the presence of NFAR proteins in both
nucleus and cytoplasm of large pyramidal neurons (Fig. 2D–E, I–J,
N–O). Non-specific staining was assessed using isotype-matched
mouse IgG (Fig. 2P–T). In GBM sections, staining with anti-
DRBP76 occurred only in areas with DAPI signal (Fig. 2U–W),
indicating exclusively nuclear localization of NFAR proteins.
Thus, immunofluorescence analyses suggested that NFAR proteins
are present in the cytoplasm of normal neurons (Fig. 2A–O), but
not in GBM (Fig. 2U–W).
Organ-Specific DRBP76 Function
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e117103. Immunoprecipitation of DRBP76 and associated
mRNPs
To confirm the identity of DRBP76 immuno-reactive material
in cytoplasmic extracts from CNS tissues and to prepare for RIP-
Chip analyses of DRBP76, we performed DRBP76 immunopre-
cipitation (IP) and co-IP analyses of NF45 (Fig. 3A). DRBP76
antibody, but not mouse isotype-matched control IgG, efficiently
precipitated the previously observed distinct immunoblot signals
from HEK293 cell- and primate brain cytosolic extracts, and
yielded co-IP of NF45 in both instances (Fig. 3A, left panel). Silver
stain analyses of the DRBP76 IPs from human/macaque normal
brain revealed the presence of the characteristic DRBP76 double-
band detected in IP immunoblots (Fig. 3A, middle panel).
Corroborating the direct immunoblot results (Fig. 1E) and the
immunofluorescence data (Fig. 2U–W), DRBP76 IP from
cytoplasmic extracts of GBM tissues did not reveal proteins in
the ,75–90 kDa size range (Fig. 3A). We speculate that a faint
band at ,110 kDa in both IPs from normal brain and GBM
represents ILF3, since our cytoplasmic extracts typically contain
nuclear contaminants (Fig. 1E). Similar IPs from cell lysates
produced the expected bands, i.e. the ,90 kDa and ,110 kDa
NFAR proteins typically isolated from transformed cell lines
(Fig. 3A, right panel).
Our observations in CNS tissues, primary CNS tumors and
various cell lines raise the possibility that the physiological role of
DRBP76 in gene regulation in the CNS may be altered in CNS
malignancy. For example, divergent isoform distribution and
subcellular localization of DRBP76 is likely to result in distinct
association with target mRNAs. To unravel potential roles in gene
regulation for DRBP76, we conducted a systematic evaluation of
DRBP76’s association with potential target mRNAs by RIP-Chip.
Ideally, such tests would directly compare mRNA pools associated
with DRBP76 isoforms unique to normal human tissues, e.g. brain
and transcripts binding to the characteristic ,90 kDa isoform
Figure 2. Immunofluorescence analyses of NFAR proteins in the human brain and in GBM. A.–O. NFAR proteins in human brain. Cryostat
sections of normal brain were treated with the indicated detection reagents. Merge 1 (Nissl:DRBP76 antibody) and 2 (Dapi:DRBP76 antibody) suggest
cytoplasmic NFAR proteins in neurons. P.–T. Control immunofluorescence with isotype-matched non-specific mouse IgG. Merge 1 (Nissl:mIgG) and 2
(Dapi:mIgG) suggest the absence of non-specific staining. U.–W. NFAR proteins in GBM. The merged image (Dapi:DRBP76 antibody) suggests
exclusive nuclear NFAR proteins in GBM cells. Bars=50 mm.
doi:10.1371/journal.pone.0011710.g002
Organ-Specific DRBP76 Function
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11710detected in CNS tumors. We thoroughly evaluated DRBP76 IPs
from lysates obtained from monkey and human brain. Due to
technical difficulties regarding yield and purity of the IP reactions
and the yield and quality of the mRNP co-precipitate, we had to
abandon this approach. Since the characteristic DRBP76 isoform
distribution in normal tissues is not recapitulated in transformed
Figure 3. Immunoprecipitation studies of DRBP76. A. Left panel. Control mouse IgG and anti-DRBP76 IP from HEK293 cells, normal primate
CNS and GBM tissues. Co-IP of NF45 was analyzed as well. Middle/Right panel. Silver stain of anti-DRBP76 immunoprecipitated material from normal
human/simian brain and from HEK293 and HTB-14 cell lines, respectively, analyzed by immunoblot. B. IP with anti-DRBP76, but not isotype-matched
control IgG, effectively removes DRBP76 from HEK293 cell lysates. C. RT-PCR of GCase and GAPDH transcript from RNA isolated from
immunoprecipitated DRBP76 RNP.
doi:10.1371/journal.pone.0011710.g003
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characteristically associated with CNS malignancy or transformed
cells. Thus, we carried out RIP-Chip analyses of DRBP76 from
HEK293 cells by IP of mRNP complexes and spotted microarray
analysis of RNAs associated with them.
First, IP effectiveness and specificity were controlled (Fig. 3).
DRBP76 IP efficiently precipitated the protein from HEK293
cytoplasmic extracts, while IP with isotype-matched control mouse
IgG neither precipitated DRBP76, nor significantly altered its
presence in post-IP supernatants (Fig. 3B). Second, RNA was
isolated from the IP reaction and RT-PCR assays were performed
by analysis of a known DRBP76 target to evaluate the specificity of
the RNP precipitation. Prior studies suggested that cytoplasmic
translation control protein (TCP80), a protein with high sequence
similarity to DRBP76 and identical dsRNA binding domains [28],
binds acid b-glucosidase (GCase) mRNA and inhibits its
translation [17]. RT-PCR analysis was performed with total
RNA purified from HEK293 cytoplasmic extract, or RNA co-
precipitated with DRBP76 antibody or with control mouse IgG.
While GCase mRNA was readily amplified from total or positive
(DRBP76) IP samples, no significant amplification was observed in
mouse isotype-matched IgG controls (Fig. 3C). Amplification of
negative control GAPDH mRNA was detected in the total RNA
samples, but only trace amounts of signal were obtained from both
mouse IgG and anti-DRBP76 IP samples (Fig. 3C).
4. Identification of DRBP76-Associated mRNAs
We used RIP-Chip to identify mRNAs associated with RNP
complexes containing DRBP76 from cytoplasmic HEK293 ex-
tracts. Five biological replicates each of DRBP76, mock (isotype-
matched mouse IgG) immunoprecipitates, and total cellular RNA
samples were analyzed using spotted cDNA microarrays that
interrogated 3.5610
4 genes. To qualify for subsequent analysis and
be defined as ‘enriched’, a probe had to be .2-fold above local
background in any of the IPs or the totals. T-scores, p-values and
log-fold changes were calculated comparing DRBP76 IP versus
mock IP for all probes expressed (n=12,468). Visual inspection of
the t-score distribution and the quantile:quantile plot indicated the
right tail of the DRBP76 vs. mock IP distribution deviated from a
normal distribution (Fig. 4A). Since probes with very high t-scores
correspond to the right tail, substantially more mRNAs were
enriched in the DRBP76 IP than the mock IP.
To determine a cut-off that may define a discrete population of
mRNAs associated with DRBP76, we applied a percentile rank
transformation, which was used in the analysis of stem loop
binding protein (SLBP) and tris-tetra-proline RIP-Chip targets
[29,30]. The DRBP76 IP average percentile rank (APR)
distribution is bimodal at the high percentile ranks, whereas the
mock IP APR distribution is normal (Fig. 4B). We defined
DRBP76 targets as those with DRBP76 IP APRs .0.95, mock IP
APRs ,0.95, and a fold enrichment over mock IP .2. Altogether,
we detected 189 putative DRBP76 target mRNAs (,1.5% of the
total 12,468 expressed) (Fig. S1). Importantly, for these putative
targets relative mRNA abundance did not account for the
association of mRNAs with DRBP76 based on the lack of
correlation between DRBP76 IPs and totals (r
2=0.04). Further,
comparing DRBP76 IPs to mock IPs also exhibited little to no
correlation (r
2=0.15), indicating the RIP-Chip successfully
isolated a subset of specific target mRNAs. Consequently,
DRBP76 IP samples clustered together relative to mock IP
samples and total mRNA samples (Fig. 5).
5. Common functional groups enriched in DRBP76 IP
We examined the putative DRBP76 target mRNAs, using gene
set enrichment analysis (GSEA) to explore known relationships
among them and to determine if proteins encoded by these
Figure 4. Identification of DRBP76-associated mRNAs using RIP-Chip. A. Distribution of DRBP76 IP vs. mock IP t-scores. Deviation of data
from the diagonal quantile:quantile plot indicates the non-Gaussian nature of the DRBP76 IP vs. mock IP distribution, corresponding with transcripts
specifically enriched in the DRBP76 IP. B. Distribution of the average percentile ranks (APR) of 5 biological replicates for DRBP76 IPs and mock IPs.
Transcripts considered DRBP76 RNP-associated are indicated by black boxes.
doi:10.1371/journal.pone.0011710.g004
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significantly enriched functional categories vital to cellular
metabolism (Fig. 5B). These include mRNAs encoding histone
proteins, ribosomal proteins, and proteins involved in oxidative
phosphorylation. Particularly striking was the enrichment of
mRNAs encoding histone proteins. In a list ranked by t-scores
representing differential enrichment between of transcripts
DRBP76 vs. mock IP, the distribution of histone transcripts was
significantly biased for being enriched in the DRBP76 IP (Fig. 6A).
Furthermore, gene sets representing mRNAs containing KRC-
TCNNNNMANAGC or TTTNNANAGCYR motifs were both
significantly enriched in the DRBP76 IPs. These motifs are present
in histone mRNAs, and overlap with the terminal conserved stem
loop (SL) in their 39UTR [31]. To validate DRBP76 histone
mRNA targets, we performed RT-PCR analysis of total RNA
isolated from HEK293 cytoplasmic extracts and corresponding
RIPs obtained with a-DRBP76 or isotype matched control mIgG
antibodies (Fig. 6B). RT-PCR amplified Hist1H4A (,48.5-fold
enriched on microarray) and Hist2H2ac (,4.9 fold enriched on
microarray) from DRBP76 IP, but not from control mouse IgG IP
(Fig. 6B).
HTB-14 glioma cells share DRBP76 isoform distribution with
HEK293 cells, but the protein is far less abundant in cytoplasm in
the former (Fig. 1F), recapitulating the situation in patient GBM
tissues (Fig. 1E). To establish whether relative cytoplasmic
exclusion of DRBP76 in HTB-14 cells produces distinct
association with mRNAs, we conducted RIP-Chip analyses from
HTB-14 cell lysates. These revealed that DRBP76-associated
mRNAs identified from HEK293 cell were indeed significantly
enriched (p,0.001) in DRBP76 RIPs from HTB-14 cells (Fig. 7A).
Furthermore, the significant enrichment of mRNAs encoding
histone proteins by DRBP76 discovered in HEK293 cells was
recapitulated in HTB-14 cells (Fig. 7B). Altogether these data
suggest a large degree of similarity between DRBP76 mRNA
targets in HEK293 and HTB-14 cells, in line with similar
DRBP76 isoform expression in these transformed cell lines.
Discussion
DRBP76 has been implicated in diverse roles of transcriptional
or post-transcriptional gene regulation, e.g., binding the interleu-
kin-2 promoter [32] and stabilizing interleukin-2 mRNA in
activated T-cells [15]. Such functional roles are likely influenced
by subcellular distribution, which controls binding to target
mRNAs or other compartment-specific functions. In tissue culture,
DRBP76 is mostly nuclear, but exhibits cytoplasmic re-distribution
when prompted by stimuli [21]. Re-distribution may dictate
function, either by withdrawing the protein from the nuclear
compartment [21] or by enabling interaction with cytoplasmic
transcripts [15]. We demonstrated that DRBP76 exhibits
intrinsically distinct subcellular distribution in primate tissues in
the absence of known stimuli. Mitosis was shown to trigger
cytoplasmic re-localization of ,90 kDa DRBP76 in cultured cells
[21]. However, ,75–80 kDa DRBP76 is present in cytoplasm in
mostly post-mitotic brain, while the ,90 kDa variant is predom-
inantly nuclear in mitotically active GBM.
The distinct electrophoretic mobility of DRBP76 proteins from
normal CNS and tumors/cell lines may stem from previously
described splice variation affecting exon 3 [25] or the 39 portion of
Figure 5. Enrichment of DRBP76-associated mRNAs and their common functional grouping. A. Heatmap displaying results of clustering
DRBP76 IP, mock IP and total mRNA levels for all DRBP76 targets (n=189). B. Gene sets significantly enriched in the DRBP76 IP vs. mock IP as
determined by GSEA. NES= normalized enrichment score, FDR= false discovery rate.
doi:10.1371/journal.pone.0011710.g005
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combined with divergent post-translational modification, e.g.
phosphorylation, methylation and acetylation to give rise to
heterogeneous DRBP76 proteins in diverse tissues. We are
currently using advanced proteomic techniques to elucidate these
differences, but preliminary analyses suggest that this is no easy
task. It is well known that protein heterogeneity influences
subcellular distribution and cellular functions of RNA-binding
proteins. A cytoplasmic locale in the CNS may explain DRBP76’s
association with and axonal transport of Tau mRNA [34] or a role
in the replication of neurotropic RNA viruses [18,19]. However,
any in vitro study of the true physiologic role of DRBP76
subcellular distribution and its dynamics is limited because the
characteristic ,75–80 kDa DRBP76 isoforms found in normal
tissues are absent in tissue culture.
DRBP76 tissue-type specific isoform diversity also has implica-
tions for RNA-binding and, thus, post-transcriptional gene
regulation. For example, while ,90 kDa DRBP76 from tissue
culture lysates binds efficiently to poly(I):(C) [35], the ,75–80 kDa
isoforms in normal brain do not (Fig. S2). Since the latter do not
occur in tissue culture, in vitro studies of DRBP76 association with
target mRNAs are limited to interpretation of such interactions in
cell lines or tumors, where our data suggest a similar ,90 kDa
DRBP76 variant is expressed.
Two previous attempts to identify DRBP76 target mRNAs have
been published; both using DRBP76 mRNPs isolated from
transformed cells [20,36]. Formaldehyde crosslinking of epitope-
tagged, ectopic protein followed by IP in HEK293 cells yielded a
previously unknown class of small, non-coding RNAs, but did not
include systematic, genome-wide analyses [36]. Since such non-
Figure 6. Significant enrichment of DRBP76-associated mRNAs encoding histone proteins in HEK293 cells. A. Transcripts rank-ordered
by t-scores representing differential enrichment in DRBP76 IP vs. mock IP from HEK 293 cells. Black lines indicate the rank of each individual histone
mRNA detected. B. Validation of histone mRNA targets by RT-PCR.
doi:10.1371/journal.pone.0011710.g006
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not confirm these interactions. We avoided using ectopic epitope-
tagged DRBP76 because the protein is abundant in HEK-293 cells
and tags can interfere with RNA-binding. Since RIP precipitates
existing RNPs, the possibility of blocking RNA recognition due to
antibody binding to DRBP76 is remote in our study [22]. Another
study reported RIP-Chip of DRBP76 from HeLa cell lysates [20].
The reported target mRNA pool from that study does not overlap
with our findings [20]. A number of factors may explain this
divergence. In all cell lines tested, the ,90 kDa DRBP76 variant
dominates, but abundance of this protein is inherently divergent in
different lines (Fig. 1B). The study by Kuwano et al. used total
HeLa cell lysates [20], while our assay employed cytoplasmic
extracts. Most importantly, methods to prepare the immunopre-
cipitated mRNP likely were distinct. We undertook a conscious
effort to optimize IP and subsequent DRBP76 mRNP purification
steps prior to microarray analysis (Fig. 3). There is little detail
regarding these procedures in Kuwano et al. [20], but different
experimental protocols may explain divergent outcomes.
The most compelling observation stemming from our studies is
the striking cell type-specific isoform distribution of DRBP76 in
transformed cells and in primary CNS tumors. Since altered
DRBP76 isoform patterns and subcellular distribution were similar
in all human tumors and in several cell lines of diverse origin, we
speculate that they may be broadly associated with malignancy.
The distinct properties of DRBP76 proteins in cancer are likely
associated with altered gene-regulatory functions in neoplasia. Our
studies indicate strong enrichment of mRNAs encoding histone,
ribosomal and oxidative/metabolic functions with the DRBP76
mRNP, consistent with the post-transcriptional operon model of
coordinated expression [3]. Cell proliferation depends upon
coordinated histone production and protein biosynthetic machin-
ery that principally involves ribosomal proteins [30,37–40].
Moreover, posttranscriptional coordination of oxidative pathways
and mitochondrial functions are well documented in S. cerevisiae
[41–43], yet this has not been elucidated in mammalian systems.
Whether DRBP76 serves such functional roles by association with
mRNAs encoding these functionally related mRNAs is yet to be
determined. In any case, there is abundant literature demonstrat-
ing the importance of ribosomal biosynthesis and oxidative
metabolism involving mitochondria and the Warburg effect in
many pathogenic processes including carcinogenesis [1,44,45]. It
will be important to determine whether DRBP76 participates in
coordinating these overlapping functions and the extent to which
they are altered in malignancy.
Materials and Methods
Ethics statement
All human CNS and CNS tumor tissues used in this study were
existing, discarded surplus pathological specimens. No human
subjects were enrolled for research purposes and this study was
declared exempt from review by the Institutional Review Board
(IRB).
Vertebrate animal tissues (from mouse and Cynomolgus macaque)
were existing, discarded surplus materials stemming from
unrelated studies. No animals were enrolled in research activities
for purposes related to this study and the tissues were not collected
with the purpose of being used in this study. Therefore, the use of
murine and simian tissues in this study does not qualify as
vertebrate animal research. This was confirmed by the Director of
the Institutional Animal Care and Use Committee (IACUC) at
Duke University Medical Center.
Cell lines, preparation of cytoplasmic extracts and
immunoblot
HEK293, HTB-14, and SH-SY5Y cells (ATCC, Manassas, VA)
were grown in Dulbecco’s Modified Eagle Medium (DMEM)
Figure 7. Significant enrichment of DRBP76-associated mRNAs from HEK 293 cells and histone mRNAs in brain tumor derived HTB-
14 cells. Transcripts rank-ordered by average percentile rank representing differential enrichment in DRBP76 IP from HTB-14 cells. A. Black lines
indicate the rank of each individual DRBP76-associated mRNA identified from HEK293 cells (p,0.001). B. Black lines indicate the rank of each
individual histone mRNA detected (p,0.001).
doi:10.1371/journal.pone.0011710.g007
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antibiotics. NHA (Lonza, Walkersville, MD) were propagated
following the manufacturer’s suggestions. Cells were scraped from
culture dishes, washed with cold PBS and pelleted by centrifugation
at4uC.Thepelletwas re-suspended inanequal volume ofpolysome
lysis buffer (PLB; 100 mM KCl, 5 mM MgCl2, 10 mM HEPES-
KOH, pH 7.0, 0.5% NP-40, 1 mM DTT and 1 mM PMSF)
supplemented with RNaseOUT (Invitrogen, Carlsbad, CA),
protease inhibitor cocktail (Sigma, St. Louis, MO) and Halt
TMpho-
sphatase inhibitor (Pierce, Rockford, IL). Lysates were incubated on
ice for 5–10 min and stored in aliquots at 280uC. The total protein
concentration of cytoplasmic lysate determined by Bradford assay
was 7–10 mg/mL. Cell lysates were fractionated using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford,
IL) following the manufacturer’s instructions. Induction of a
neuron-like phenotype in SH-SY5Y cells with ATRA was carried
out as reported before [46]. Normal simian brain tissues were
obtained from the Center of Biological Evaluation and Research,
Food and Drug Administration and mouse tissues were surplus
discarded pathological specimens stemming from unrelated studies
in the laboratory. It is estimated that the autolysis time for fresh
frozen monkey and mouse tissues was less then 30 min. Normal
human brain tissues were obtained from the New York Brain Bank,
Columbia University. The tissues were dissected during autopsy
from deceased patients without history of neurological illness. The
approximate autolysis time for human brain samples was 24–
32 hours. Human glioblastoma multiforme (GBM) samples were
fresh-frozen, surplus pathological specimens obtained at the time of
craniotomy. Tissue samples were gently thawed, dissected into
,1m m
3 fragments, washed with cold PBS and homogenized in 5
volumes of cold brain lysis buffer (BLB; 150 mM NaCl, 50 mM
HEPES-KOH, pH 7.3, 10% glycerol, 1 mM EDTA, 5 mM
EGTA, 0.5% NP-40, 2.5 mM DTT and 1 mM PMSF) supple-
mented with RNAse, phosphatase and protease inhibitors as
described above. The samples were lysed on ice for 30 min and
stored in aliquots at 280uC. Thereafter, lysates were centrifuged
and supernatants purified with Handee
TM Spin Columns (Pierce).
Pellets werere-suspended in equal volume of lysis buffer and used as
nuclear fraction. Total protein concentration in cytoplasmic lysates
was determined by Bradford assay. For immunoblot analyses,
proteins were resolved by electrophoresis in 4–12% Bis-Tris
NuPAGE gels (Invitrogen) and transferred to PROTRAN nitro-
cellulose membrane (Schleicher & Schuell, Keene, NH). Seven %
Tris-Acetate NuPAGE gels (Invitrogen) were used for more efficient
protein separation in 70–100 kDa region. After overnight blocking
in Startingblock T20 buffer (Pierce) membranes were incubated
with anti-DRBP76 antibody (BD Biosciences, Franklin Lakes, NJ)
for 1 h, followed by three washes with PBST (1xPBS, 0.1% Tween-
20)and1 h incubationwithsecondary HRP-conjugated anti-mouse
antibody. After three washes, signal was detected by enhanced
chemiluminescence (West Pico Substrate; Pierce) followed by
autoradiography.
Immunofluorescence
Normal human brain tissues were surplus pathological speci-
mens (parietal cortex) obtained during craniotomy from epilepsy
patients histopathologically confirmed to consist of normal human
CNS. GBM patient samples were histopathologically confirmed to
be free of contaminating CNS. Immunostaining of normal human
brain and GBM cryosections (4 mm) was performed as follows.
Sections were fixed with cold 4% paraformaldehyde in PBS for
15 min, permeabilized with 220uC methanol for 10 min, blocked
with 5% goat serum in PBS for 1 h and incubated overnight at
4uC with anti-DRBP76 antibody diluted in blocking buffer at
1:1000 or equal amount of isotype-matched mouse IgG1 control
to rule out nonspecific staining. Then, slides were washed with
PBS and incubated for 45 min at room temperature with FITC-
conjugated anti-mouse IgG (Sigma) at a 1:150 dilution. After 3
washes with PBS, normal brain sections were treated with
NeuroTrace Fluorescent Nissl Stain (Invitrogen), a neuronal cell
marker. Staining was performed for 20 min at room temperature
with red NeuroTrace stain at a 1:1000 dilution. Following 2 h
wash with PBS, both normal brain and GBM sections were treated
with 1 mM CuSO4 in 50 mM NH4OAc (pH 5.0) for 90 min at
room temperature to reduce lipofuscin autofluorescence [47].
Sections were washed and mounted in ProLong Gold antifade
reagent with 49,69-diamidino-2-phenylindole (DAPI; Invitrogen).
Images were collected using an XI50 Olympus microscope, DP70
digital camera, and DPController/DPManager software. Images
were processed and analyzed using Adobe Photoshop software.
IP of endogenous DRBP76 RNP complexes
IP of mRNP complexes from HEK293 or HTB-14 cytoplasmic
lysates was generally carried out as described before [22]. Briefly,
protein-G sepharose beads were pre-swollen in NT2 buffer
(150 mM NaCl, 50 mM tris-HCl, pH 7.5, 1 mM MgCl2, 0.05%
NP-40) supplemented with 1% BSA and coated with 20 mgo f
DRBP76 antibody or mouse IgG1 as isotype negative control
(both BD Biosciences) overnight at 4uC. Unbound antibody was
rinsed off 5 times with 1 mL of cold NT2 buffer and beads were
incubated with pre-cleared cytoplasmic lysate for 4 hrs at 4uC.
Thereafter, supernatant was collected for immunoblot/RNA
isolation and beads were washed twice with BD buffer (150 mM
NaCl, 10 mM tris-HCl, pH 7.5, 0.5% NP-40, 1% Triton X-100,
1 mM EDTA, 1 mM EGTA and 1 mM DTT) supplemented with
1 M urea and 4 times with BD buffer only. During the last wash
10% of beads were removed for immunoblot and the remaining
beads were resuspended in 100 mL NT2 buffer and processed for
RNA isolation. The amount of cytoplasmic lysate used for each IP
was equivalent to 1 mg of total protein.
RNA purification and reverse transcription (RT)-PCR
RNA bound to the beads after IP with DRBP76 antibody or
mouse IgG1 control, or total RNA from cytoplasmic lysates was
purified using Trizol Reagent (Invitrogen) as described elsewhere
[22]. The RNA concentration and purity (OD260:280 ratio) was
determined on a Nanodrop spectrometer and the integrity of the
RNA samples was verified by electrophoresis using the Reliant Gel
System (Cambrex, East Rutherford, NJ). Ten mg of RNA per
sample were submitted to the Duke University Microarray Core
Facility for spotted array analysis. Five biological replicates of each
sample were analyzed. RNA from total lysate and from the IPs was
subjected to RT with oligo-dT (Ambion, Foster City, CA). Gene
specific primers and Sahara Mix (Bioline, Taunton, MA) were
used to amplify target genes identified in microarray. These tests
included primer pairs (1) 59-actcaccacaatgtccgcct-39 and (2) 59-
ggagccctcaggaatgaact-39 (GCase), (3) 59-gtctggacgtggtaaggg-39 and
(4) 59-gcctttggttcagaaatgcaag-39 (Hist1 H4A), (5) 59-ctggtcgtgg-
caaacaag-39 and (6) 59-cctggatgttaggcaaaacg-39 (Hist2 H2ac) or (7)
59-catgttcgtcatgggtgtgaacca-39 and (8) 59-agtgatggcatggactgtggtcat-
39 (GAPDH).
Microarray data analysis
Arrays were printed at the Duke Microarray Facility using the
Genomics Solutions OmniGrid300 Arrayer and contained
Human Operon v4.0.1 oligo set (Oligo Source) consisting of
,3.6610
4 unique 70-mers. For all arrays RNA was assayed using
direct labeling of experimental samples (Cy 3) and Stratagene
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submitted to the GEO, GSE20001. All arrays were subject to loss
normalization within each array and scale normalization across
arrays using Array Magic [48]. Replicate probes were collapsed to
the median value. Probes had to have signal .2-fold than local
background in all biological replicates for any of the RIPs or the
totals at any time point to be considered for subsequent analysis.
Gene Pattern [49] was used to calculate t-scores, p-values and log
fold changes comparing the DRBP76 and mock IPs. Gene set
enrichment analysis (GSEA) [50] was used to determine gene sets
significantly enriched in the DRBP76 IP. Only gene sets with false-
discovery-rate (FDR) q-values of,0.05 or family-wise-error-rates
(FWER) of,0.1 were considered significant. For each probe, a
DRBP76 IP average percentile rank and mock IP average
percentile rank was calculated as the average of the individual
percentile ranks from each of the 5 biological replicates of the
DRBP76 and mock IPs, respectively. Probes with a DRBP76 IP
average percentile rank (APR) of .0.95, mock IP APR of,0.95,
and a fold enrichment over mock IP.2 were considered DRBP76
targets. A heatmap depicting their relative hybridization values in
the DRBP76 IP, IgG IP and total mRNA was created using Gene
Pattern and Java Treeview [51].
Supporting Information
Figure S1 List of putative DRBP76 target mRNAs in HEK293
cells.
Found at: doi:10.1371/journal.pone.0011710.s001 (0.16 MB
XLS)
Figure S2 Poly(I):(C) binding studies. Binding of DRBP76
proteins from HEK293 cells (top) and Cynomolgus brain lysates
(bottom) to poly(I):(C) sepharose.
Found at: doi:10.1371/journal.pone.0011710.s002 (0.59 MB TIF)
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